Seminars in hematology最新文献_第9页

CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail? CD19 CAR-T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤；为何会失败？

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.11.007

Hannah Kinoshita , Catherine M. Bollard , Keri Toner

引用次数: 0

Biological heterogeneity in diffuse large B-cell lymphoma 弥漫大b细胞淋巴瘤的生物学异质性

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.11.006

Laura K. Hilton , David W. Scott , Ryan D. Morin

引用次数: 0

DLBCL arising from indolent lymphomas: How are they different? 由惰性淋巴瘤引起的DLBCL:它们有何不同?

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.11.002

Erin M. Parry , Sandrine Roulland , Jessica Okosun

引用次数: 0

Antibody and immunotherapy in diffuse large B-cell lymphoma 弥漫大 B 细胞淋巴瘤的抗体和免疫疗法。

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.11.001

Allison Barraclough , Eliza A. Hawkes

引用次数: 0

outside front cover, PMS 8883 metallic AND 4/C 外部前盖，PMS 8883金属和4/C

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/S0037-1963(24)00032-5

引用次数: 0

Integration of PET in DLBCL 正电子发射计算机断层显像与 DLBCL 的整合

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.12.003

Katharine L Lewis , Judith Trotman

引用次数: 0

Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options DLBCL 的二线治疗：选择的演变

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.12.001

N. Fabbri , A. Mussetti , A. Sureda

{"title":"Second-line treatment of diffuse large B‐cell lymphoma: Evolution of options","authors":"N. Fabbri , A. Mussetti , A. Sureda","doi":"10.1053/j.seminhematol.2023.12.001","DOIUrl":"10.1053/j.seminhematol.2023.12.001","url":null,"abstract":"<div><div>In the era of immunochemotherapy, approximately 60%-70% of diffuse large B-cell lymphoma (DLBCL) patients achieve remission with first-line rituximab-based chemoimmunotherapy<span><span><span><span>. However, 30%-40% relapse after initial response to first-line therapy and, out of them, 20%-50% are refractory or experience early relapse. The second-line therapy algorithm for DLBCL has recently evolved, thanks to the recent approval of new therapeutic agents or their combinations. The new guidelines suggest a stratification of relapsed/refractory (R/R) DLBCL based on the time to relapse. For transplant-eligible patients, autologous stem cell transplant remains the preferred option when the patient relapses after 12 months from diagnosis, while anti-CD19 CART-cell therapy is the current preferred choice for high-risk DLBCL, defined as primary refractory or relapse ≤12 months. For transplant-ineligible or CAR T-cell therapy-ineligible patients, the therapeutic arsenal historically lacked effective options. However, new therapeutic options, including </span>polatuzumab vedotin<span> combined with bendamustine-rituximab and tafasitamab with lenalidomide<span>, have been recently approved, and novel agents such as loncastuximab tesirine, </span></span></span>selinexor, anti-CD19 CAR T-cell therapy, and </span>bispecific antibodies have shown promising efficacy and manageable safety in this setting offering new hope to patients in this challenging scenario.</span></div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 5","pages":"Pages 305-312"},"PeriodicalIF":5.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138744989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence-based management of primary and secondary CNS lymphoma 原发性和继发性中枢神经系统淋巴瘤的循证管理

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.11.003

Jahanzaib Khwaja , Lakshmi Nayak , Kate Cwynarski

{"title":"Evidence-based management of primary and secondary CNS lymphoma","authors":"Jahanzaib Khwaja , Lakshmi Nayak , Kate Cwynarski","doi":"10.1053/j.seminhematol.2023.11.003","DOIUrl":"10.1053/j.seminhematol.2023.11.003","url":null,"abstract":"<div><div><span><span><span>Central nervous system (CNS) lymphoma has traditionally had very poor outcomes however advances in management have resulted in dramatic improvements and long-term survival of patients. We describe the evidence for treatment strategies for these aggressive disorders. In </span>primary CNS lymphoma there are randomized trial data to inform treatment decisions but these are lacking to guide management in secondary CNS lymphoma. Dynamic assessment of patient fitness and </span>frailty<span><span> is key throughout treatment, alongside delivery of CNS-bioavailable therapy and enrolment in clinical trials, at each stage of the disease. Intensive high-dose methotrexate-containing induction followed by consolidation with </span>autologous stem cell transplantation with thiotepa-based conditioning is recommended for patients who are fit. Less intensive </span></span>chemoimmunotherapy<span><span>, novel agents (including Bruton tyrosine kinase inhibitors, cereblon targeting immunomodulatory agents, and checkpoint inhibitors in the context of clinical trials), and </span>whole brain radiotherapy may be reserved for less fit patients or disease which is chemoresistant. Data regarding the efficacy of chimeric antigen receptor T-cells therapy is emerging, and concerns regarding greater toxicity have not been realized. Future areas of prospective studies include the identification of those at high risk of developing CNS lymphoma, management in elderly or frail patients as well as incorporating novel agents into regimens, particularly for those with chemoresistant disease.</span></div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 5","pages":"Pages 313-321"},"PeriodicalIF":5.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138506375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction to series: Diffuse large B-cell lymphoma 系列介绍：弥漫大 B 细胞淋巴瘤

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2024.01.010

Sonali M. Smith , Laura Pasqualucci

引用次数: 0

Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023 2023 年嵌合抗原受体 T 细胞疗法在治疗 LBCL 中的有效排序

IF 5 3区医学

Seminars in hematology Pub Date : 2023-11-01 DOI: 10.1053/j.seminhematol.2023.12.002

Christine E. Ryan, Caron A. Jacobson

{"title":"Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023","authors":"Christine E. Ryan, Caron A. Jacobson","doi":"10.1053/j.seminhematol.2023.12.002","DOIUrl":"10.1053/j.seminhematol.2023.12.002","url":null,"abstract":"<div><div><span><span>Over the last decade, CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has profoundly changed the management of relapsed/refractory large-B-cell lymphoma (LBCL). At present, there are three FDA-approved anti-CD19 CAR T-cell products for LBCL: </span>axicabtagene ciloleucel (axi-cel), </span>lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Two of these (axi-cel & liso-cel) are approved for use in the second-line setting under certain conditions. As CAR T-cell therapy continues to define a new role in the treatment armamentarium for LBCL, questions remain regarding which product to use and how to sequence CAR T-cell therapy with other therapeutic options. Here we will briefly review the key features of each FDA-approved anti-CD19 CAR T-cell product and the data that led to regulatory approval for each. Next, we will focus on the recent landmark studies that have established the use of CAR T-cell therapy as second-line treatment. While no direct prospective head-to-head comparisons exist of the 3 constructs, we will review some retrospective studies that suggest some emerging differences between the products. Lastly, we will turn our attention to the horizon as we explore some of the ongoing questions of how to best leverage the curative potential of CAR T-cell therapy for the most effective management of LBCL. These areas include the consideration of CAR T-cell therapy in the frontline setting, the optimal timing for CAR T-cell referral, the optimal bridging approach, and how to continue advancing novel CAR T-cell approaches in the context of the current treatment landscape.</div></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 5","pages":"Pages 322-328"},"PeriodicalIF":5.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138818624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0